Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Cliff Continues in 2014, But Not So Steeply

Executive Summary

Most of big pharma has crossed to the other side of the patent cliff and put their biggest losses behind them in 2012 and 2013, but a few major blockbusters will face new generic competition this year, including Nexium, Copaxone, and Nasonex.

You may also be interested in...



First Generic Approvals Decline For Fourth Straight Year At US FDA

Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.

First Generic Approvals Decline For Fourth Straight Year At US FDA

Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.

Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure

Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS055872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel